OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Margulis on Different Approaches to Adjuvant Therapy in RCC

November 30th 2016

Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.

Dr. Eytan Stein on Novel Combinations in AML

November 29th 2016

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the potential combinations that could be explored with novel agents in the treatment of patients with acute myeloid leukemia.

Dr. Tanios Bekaii-Saab on Sequencing Questions in mCRC

November 29th 2016

Tanios Bekaii-Saab, MD, a professor of Medicine at Mayo Clinic, discusses sequencing regorafenib (Stivarga) and TAS-102 (Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Bryan Mehlhaff on PSA's Role in Prostate Cancer

November 29th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses the controversy surrounding prostate-specific antigen (PSA) testing in prostate cancer.

Dr. Birrer on Remaining Challenges in Cervical Cancer

November 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the remaining challenges in treating patients with cervical cancer.

Dr. Marshall on the Safety Profile of Y-90 in Colorectal Cancer

November 29th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.

Dr. Rathkopf on Investigative Agents in Prostate Cancer

November 28th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses agents being explored as treatments for patients with prostate cancer, including apalutamide and PARP inhibitors.

Dr. Sandler on Chemotherapy Combination Regimens in Prostate Cancer

November 28th 2016

Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.

Dr. Abida on Choosing Between Chemotherapy and Targeted Agents for Patients With Prostate Cancer

November 24th 2016

Wassim Abida, MD, PhD, assistant member and assistant attending physician in the Genitourinary Oncology Program at Memorial Sloan Kettering Cancer Center, discusses treatment options for patients with prostate cancer.

Dr. Oh on the Role of Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

November 23rd 2016

William K. Oh, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses the role of docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer.

Dr. Levine on Recent Progress in Cervical Cancer

November 23rd 2016

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.

Dr. Carey on QOL Changes Seen in Patients With Breast Cancer

November 23rd 2016

Lisa Carey, MD, associate director, Clinical Research, UNC Lineberger Comprehensive Cancer Center, Richardson and Marilyn Jacobs Preyer Distinguished Professorship for Breast Cancer Research, UNC-Chapel Hill, discusses how she has seen various agents impact quality of life (QOL) when used to treat patients with breast cancer.

Dr. Kumar on Future Treatment Landscape of Multiple Myeloma

November 23rd 2016

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses his vision for the future treatment landscape of multiple myeloma.

Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer

November 23rd 2016

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.

Dr. John L. Marshall on Y-90 in Colorectal Cancer

November 23rd 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses Y-90 in metastatic castration resistant colorectal cancer (mCRC).

Dr. Muggia on Combination Treatments in Ovarian Cancer

November 23rd 2016

Franco M. Muggia, MD, professor, Department of Medicine, NYU Langone Medical Center, discusses combination treatments currently being tested for the treatment of patients with ovarian cancer.

Dr. Osarogiagbon on Improving Lung Cancer Cure Rates

November 23rd 2016

Raymond U. Osarogiagbon, MD, FACP, Boston Baskin Cancer Foundation, Baptist Memorial Medical Group, discusses treating patients with lung cancer that have the potential to be cured.

Dr. Vokes on the Treatment Landscape of Recurrent Head and Neck Cancer

November 23rd 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the treatment landscape of recurrent head and neck cancer.

Dr. Marcom on Impact of FALCON Trial on HR+ Breast Cancer

November 22nd 2016

Paul Kelly Marcom, MD, associate professor of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact that the FALCON trial findings have had on the field of hormone receptor-positive breast cancer.